Branded Generics Market Segmentation With Comprehensive Analysis On Novartis, Abbott, STADA, Lupin Pharmaceuticals, Teva Pharmaceuticals, Aurobindo Pharma, Allergan, Aspen Pharma, Cipla, Mylan

“Branded Generics”
Branded Generics Market By Product Type (Value-Added Branded Generics, Trade Named Generics), Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics & Anti-Inflammatory, Others), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptic, Others), Consumption Type and Geography

This branded generics market report is a complete overview of the market that covers various aspects of product definition, market segmentation based on various parameters, and the existing vendor landscape. Branded generics company snapshot, geographical presence, product portfolio, and recent developments are taken into consideration for studying the company profiles. Moreover, this branded generics market report includes momentous data, current market trends, market environment, technological innovation, upcoming technologies and the technical progress in the related industry

Global branded generics market is expected to rise from its initial estimated value of USD 232.83 billion in 2018 to a projected value of USD 421.15 billion by 2026, registering a CAGR of 7.69% in the forecast period of 2019-2026. This rise in market value can be attributed to growing need for cheaper treatment options and pharmaceutical drugs required by patients.

Get Free Sample of This Market Information: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-branded-generics-market

Market Definition: Global Branded Generics Market

Branded generic can be defined as those pharmaceutical drugs that have been re-released with a different brand name. These drugs are produced by various pharmaceutical manufacturing companies as the patent of this drug has already expired and the generic drugs are sold at a lower cost. Even though, there isn’t any difference in the quality or manufacturing process of the drug.

Key Market Competitors: Global Branded Generics Market

Teva Pharmaceutical Industries Ltd.; Zydus Cadila; Hetero; AstraZeneca; Mylan N.V.; Novartis AG; Pfizer Inc.; GlaxoSmithKline plc; Aspen Holdings; Bausch Health; Eris Lifesciences Limited; Par Pharmaceutical; Sanofi; Apotex Inc.; Dr. Reddy’s Laboratories Ltd.; Abbott; Sun Pharmaceutical Industries Ltd.; Lupin Pharmaceuticals, Inc.; ALLERGAN; Stada Arzneimittel; Cipla Inc. and EVA PHARMA are few of the major competitors currently working in the branded generics market.

Market Drivers:

  • Growth in the number of patents expired and expiring for the branded drugs; this factor is one of the major factors driving the market growth
  • Growth in the incidents and population suffering from chronic diseases and disorders; this factor is expected to drive the market growth

Market Restraint:

  • Lack of penetration associated with the number of generic drugs worldwide; this factor is expected to act as a restraint to the market growth

Key Developments in the Market:

  • In January 2019, Hetero announced the launch of generic version of “lapatinib” in India, which will be commercialized as “Hertab” by Hetero Healthcare Ltd.
  • In February 2018, Hetero announced the launch of a generic fixed-dose combination (FDC) drug of “emtricitabine” and “tenofovir alafenamide” in India. The product has already been approved by Drug Controller General of India (DCGI) will be commercialized as “Tafero-EM” by Hetero Healthcare Ltd.
  • In November 2017, Eris Lifesciences Limited announced that they had agreed to acquire the branded generics division of Strides Shasun Limited. This acquisition will help in establishing Eris Lifesciences Limited as one of the top ten companies worldwide for Central Nervous System treatment segment.

Get TOC For Full Analysis Of Report: https://databridgemarketresearch.com/toc/?dbmr=global-branded-generics-market

Competitive Analysis: Global Branded Generics Market

Global branded generics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of branded generics market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Segmentation: Global Branded Generics Market

  • By Product Type
    • Value-Added Branded Generics
    • Trade (Brand) Named Generics
  • By Therapeutic Application
    • Oncology
    • Cardiovascular Diseases
    • Diabetes
    • Neurology
    • Gastrointestinal Diseases
    • Dermatology Diseases
    • Analgesics & Anti-Inflammatory
    • Others
  • By Drug Class
    • Alkylating Agents
    • Antimetabolites
    • Hormones
    • Anti-Hypertensive
    • Lipid Lowering Drugs
    • Anti-Depressants
    • Anti-Psychotics
    • Anti-Epileptic
    • Others
  • By Consumption Type
    • Oral
    • Parenteral
    • Topical
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
  • By Geography
    • North America
  •  
  • Canada
  • Mexico
    • South America
  • Brazil
  • Argentina
  • Rest of South America
    • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Turkey
  • Belgium
  • Netherlands
  • Switzerland
  • Rest of Europe
    • Asia-Pacific
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Singapore
  • Thailand
  • Malaysia
  • Indonesia
  • Philippines
  • Rest of Asia Pacific
    • Middle East & Africa
  • South Africa
  • Egypt
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Rest of Middle East & Africa

 

Reasons to Purchase this Report

  • Current and future of global branded generics market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Want Full Report? Enquire Here: https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-branded-generics-market

About Us

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

This branded generics market report is a complete overview of the market that covers various aspects of product definition, market segmentation based on various parameters, and the existing vendor landscape. Branded generics company snapshot, geographical presence, product portfolio, and recent developments are taken into consideration for studying the company profiles. Moreover, this branded generics market report includes momentous data, current market trends, market environment, technological innovation, upcoming technologies and the technical progress in the related industry
Global branded generics market is expected to rise from its initial estimated value of USD 232.83 billion in 2018 to a projected value of USD 421.15 billion by 2026, registering a CAGR of 7.69% in the forecast period of 2019-2026. This rise in market value can be attributed to growing need for cheaper treatment options and pharmaceutical drugs required by patients.
Get Free Sample of This Market Information: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-branded-generics-market
Market Definition: Global Branded Generics Market
Branded generic can be defined as those pharmaceutical drugs that have been re-released with a different brand name. These drugs are produced by various pharmaceutical manufacturing companies as the patent of this drug has already expired and the generic drugs are sold at a lower cost. Even though, there isn’t any difference in the quality or manufacturing process of the drug.
Key Market Competitors: Global Branded Generics Market
Teva Pharmaceutical Industries Ltd.; Zydus Cadila; Hetero; AstraZeneca; Mylan N.V.; Novartis AG; Pfizer Inc.; GlaxoSmithKline plc; Aspen Holdings; Bausch Health; Eris Lifesciences Limited; Par Pharmaceutical; Sanofi; Apotex Inc.; Dr. Reddy’s Laboratories Ltd.; Abbott; Sun Pharmaceutical Industries Ltd.; Lupin Pharmaceuticals, Inc.; ALLERGAN; Stada Arzneimittel; Cipla Inc. and EVA PHARMA are few of the major competitors currently working in the branded generics market.
Market Drivers:

  • Growth in the number of patents expired and expiring for the branded drugs; this factor is one of the major factors driving the market growth
  • Growth in the incidents and population suffering from chronic diseases and disorders; this factor is expected to drive the market growth

Market Restraint:

  • Lack of penetration associated with the number of generic drugs worldwide; this factor is expected to act as a restraint to the market growth

Key Developments in the Market:

  • In January 2019, Hetero announced the launch of generic version of “lapatinib” in India, which will be commercialized as “Hertab” by Hetero Healthcare Ltd.
  • In February 2018, Hetero announced the launch of a generic fixed-dose combination (FDC) drug of “emtricitabine” and “tenofovir alafenamide” in India. The product has already been approved by Drug Controller General of India (DCGI) will be commercialized as “Tafero-EM” by Hetero Healthcare Ltd.
  • In November 2017, Eris Lifesciences Limited announced that they had agreed to acquire the branded generics division of Strides Shasun Limited. This acquisition will help in establishing Eris Lifesciences Limited as one of the top ten companies worldwide for Central Nervous System treatment segment.

Get TOC For Full Analysis Of Report: https://databridgemarketresearch.com/toc/?dbmr=global-branded-generics-market
Competitive Analysis: Global Branded Generics Market
Global branded generics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of branded generics market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Segmentation: Global Branded Generics Market

  • By Product Type
    • Value-Added Branded Generics
    • Trade (Brand) Named Generics
  • By Therapeutic Application
    • Oncology
    • Cardiovascular Diseases
    • Diabetes
    • Neurology
    • Gastrointestinal Diseases
    • Dermatology Diseases
    • Analgesics & Anti-Inflammatory
    • Others
  • By Drug Class
    • Alkylating Agents
    • Antimetabolites
    • Hormones
    • Anti-Hypertensive
    • Lipid Lowering Drugs
    • Anti-Depressants
    • Anti-Psychotics
    • Anti-Epileptic
    • Others
  • By Consumption Type
    • Oral
    • Parenteral
    • Topical
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
  • By Geography
    • North America
  • Canada
  • Mexico
    • South America
  • Brazil
  • Argentina
  • Rest of South America
    • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Turkey
  • Belgium
  • Netherlands
  • Switzerland
  • Rest of Europe
    • Asia-Pacific
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Singapore
  • Thailand
  • Malaysia
  • Indonesia
  • Philippines
  • Rest of Asia Pacific
    • Middle East & Africa
  • South Africa
  • Egypt
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Rest of Middle East & Africa

Reasons to Purchase this Report

  • Current and future of global branded generics market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Want Full Report? Enquire Here: https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-branded-generics-market
About Us
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.
Contact Us
Data Bridge Market ResearchToll Free: +1-888-387-2818Mail: sopan.gedam@databridgemarketresearch.comhttps://databridgemarketresearch.com

Media Contact
Company Name: Data Bridge Market Research Private Limited
Contact Person: Sopan Gedam
Email: Send Email
Phone: +1-888-387-2818
Address:Office Number 402, Amanora Chambers, Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://databridgemarketresearch.com/reports/global-branded-generics-market/